CRXX CombinatoRx, Incorporated featured news, full reports, and detailed charts
CombinatoRx, Incorporated (CRXX) Wrap Up:
We are a biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a broad portfolio of product candidates in phase 2 clinical development. Going beyond traditional combinations, we create product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in our portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from our proprietary combination high throughput screening, or cHTSTM technology, which provides a renewable and previously untapped source of novel drug candidates. We are currently developing a clinical portfolio of product candidates targeting multiple diseases including immuno-inflammatory diseases, topical dermatoses and metabolic disease. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f13%2f0001193125-08-055550.html#FIS_BUSINESS"www.combinatorx.com
73 Employees
Founded in 2000
CombinatoRx, Incorporated (CRXX:NASDAQ)
LAST $0.88 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of November 19, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of CombinatoRx, Incorporated (CRXX)
|
OPEN
--
|
PREVIOUS CLOSE
$0.88
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
09/16/09 - $2.60
|
52 WEEK LOW
01/26/09 - $0.25
|
|
|
MARKET CAP
30.9M
|
AVERAGE VOLUME 3 mo
1.2M
|
|
|
DILUTED EPS TTM
$-1.12
|
SHARES OUTSTANDING
35.1M
|
|
|
CRXX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
CombinatoRx Has A Rich Pipeline
05/21/2007 5:00 AM ET
CRXX Top Compensated Officers
Mr. Robert Forrester LL.B.
Chief Executive Officer and Interim President
Age: 46
Total Annual Compensation: $446.5K
Mr. Jason F. Cole Esq.
Senior Vice President, Secretary and General ...
Age: 36
Total Annual Compensation: $345.5K
Ms. Lynn Baird Ph.D.
Consultant
Age: 61
Total Annual Compensation: $294.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for CombinatoRx, Incorporated (CRXX)
CombinatoRx, Incorporated expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
11/5/2009
CombinatoRx, Incorporated expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
CombinatoRx, Incorporated Announces Unaudited Condensed Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2009
11/3/2009
CombinatoRx, Incorporated announced unaudited condensed consolidated financial results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net loss of $8.26 million or $0.24 per basic and diluted share on total revenue of $2.74 million compared to net loss of $15.56 million or $0.45 per basic and diluted share on total revenue of $2.99 million for the same period a year ago. Operating loss was $8.29 million compared to $14.59 million for the same period a year ago. Loss from continuing operations before provision for income taxes was $8.26 million compared to $14.36 million for the same period a year ago. Loss from continuing operations was $8.26 million or $0.24 per basic and diluted share compared to $14.36 million or $0.41 per basic and diluted share for the same period a year ago. For the nine months, the company reported net loss of $9.78 million or $0.28 per basic and diluted share on total revenue of $8.69 million compared to net loss of $49.89 million or $1.43 per basic and diluted share on total revenue of $8.85 million for the same period a year ago. Operating loss was $24.07 million compared to $48.06 million for the same period a year ago. Loss from continuing operations before provision for income taxes was $23.89 million compared to $46.50 million for the same period a year ago. Loss from continuing operations was $23.89 million or $0.68 per basic and diluted share compared to $46.52 million or $1.34 per basic and diluted share for the same period a year ago.
CombinatoRx, Incorporated, Annual General Meeting, Nov 30, 2009
11/3/2009
CombinatoRx, Incorporated, Annual General Meeting, Nov 30, 2009, at 09:00 US Eastern Time. Location: Goodwin Procter LLP, 53 State Street, Boston, MA 02109, Massachusetts,United States. Agenda: To vote on matters related to the proposed merger with Neuromed Pharmaceuticals Inc .
CRXX Competitors
| Company | Last | Change |
| Caliper Life Sciences Inc | $2.70 USD | -0.052 |
| Ore Pharmaceutical Holdings Inc | $0.63 USD | -0.0036 |
| Vanda Pharmaceuticals Inc | $10.41 USD | -0.16 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CRXX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.6x |
|
| Price/Book | 2.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.2x |
|
|
CRXX |
||
|
CRXX transactions
| Type Date |
Target |
|
Merger/Acquisition
June 30, 2009 |
Neuromed Pharmaceuticals, Ltd. |
|
Merger/Acquisition
June 2, 2009 |
Combinatorx Singapore Pte Ltd. |
More Recent News About CombinatoRx, Incorporated
More news for CRXX
CombinatoRx Reports Financial Results for the Third Quarter 2009
CombinatoRx, Incorporated Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (Unaudited)    Three months ended September 30, Nine months ended September 30, 2009 2008 2009 2008  As Adjusted  As Adjusted  Revenue Collaborations $ 2,602 $ 2,778 $ 7,936 $ 8,215 ...Click here to read the whole Article (external link)
CombinatoRx narrows loss on deep R&D cuts
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
COMBINATORX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement
Show all filings for COMBINATORX, INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for COMBINATORX, INC 3-Nov-2009Results of Operations and Financial Condition, Other Events, Financial Statement Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information prov...Click here to read the whole Article (external link)
Neuromed Receives FDA Feedback on New Drug Application for Exalgo Extended-Release Tablets
CAMBRIDGE, Mass. & VANCOUVER--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - NewsTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time, with staff from the United States Food and Drug Administration (FDA). In these discussions, the FDA staff indicated that the NDA in its current form would not be sufficient to form the basis for approval of Exalgo under Section 505(b)(1) of the Food, Drug and Cosmetic Act of 1938, as amended (FDCA). Based on these discussions with the FDA, Neuromed is working with Mallinckrodt, Inc., who owns the commercial rights to Exalgo, to determine the appropriate actions to be taken based on the discussions with the staff of the FDA, which actions may include amending the existing NDA, or potentially resubmitting the NDA under Section 505(b)(2) of the FDCA, which utilizes different criteria to determine the basis for approval of a new drug candidate. So that each company's stockholders can be provided with additional information regarding these developments, CombinatoRx and Neuromed each plan to convene their respective stockholders meetings at the previously scheduled times and then adjourn these meetings until, in the case of CombinatoRx, 9:00 a.m. ET on November 30, 2009, at the offices of ...Click here to read the whole Article (external link)
COMBINATORX, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibit
Show all filings for COMBINATORX, INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for COMBINATORX, INC 10-Nov-2009Termination of a Material Definitive Agreement, Financial Statements and Exhibit Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided...Click here to read the whole Article (external link)
COMBINATORX, INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Sprint, CombinatoRx: Early Volume Plays
Stock quotes in this article: NABI , NLST , CADC , ...Click here to read the whole Article (external link)
COMBINATORX, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for COMBINATORX, INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for COMBINATORX, INC 16-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purp...Click here to read the whole Article (external link)
CombinatoRx Shares Fall as Neuromed Drug Not Approved by FDA
Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business Advertise with us | Jobs at FOX Business Network | Internships at FBN Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com. Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions. This material may not be published, broadcast, rewritten, or redistributed. ©2009 FOX News Network, LLC. All rights reserved. ...Click here to read the whole Article (external link)
Would you like to leave a comment about CombinatoRx, Incorporated CRXX
Find out what social network information about CombinatoRx, Incorporated are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides CombinatoRx, Incorporated there is more great information available at Realpennies.com